According to a study from researchers at the Johns Hopkins University and others, convalescent plasma therapy was found to reduce hospital admissions for COVID-19 by 54%, if the treatment was administered within 8 days of onset of symptoms.

A total of 1181 adults were randomized to receive treatment with either high-titer convalescent plasma or placebo. About 2.9% of those who received the therapy were admitted to the hospital compared to 6.3% of those who were given placebo control plasma. This amounted to a 54% risk reduction for hospitalization with convalescent plasma therapy.

The study’s principal investigator, David Sullivan, a professor at Johns Hopkins Bloomberg School of Public Health, Baltimore, said that this shows a clear difference. The researchers stated that while several studies of convalescent plasma have been conducted in hospitalized patients, this is one of the few studies done in outpatients. The study appears on medRxiv and has yet to be peer reviewed… (Medscape)